Our focus is on novel drugs for treatment of widespread metabolic disorders, within the field of life style induced diseases such as Obesity, Type 2 Diabetes and Hypertension. 
BBR's Proprietary Funnel Process:
Bridge BioResearch Limited (BBR) continuously monitors databases for drug
development and patents within the area of Obesity, Type 2 Diabetes and related Metabolic Disorders.
Targets are carefully selected for evaluation through our proprietary assessment tool which is based on validation of the outcome of hundreds of published development projects.
Careful selection, tests and research follows, including studies about freedom to operate, proof of concept as well as preclinical work.
Various criteria over time are used to closely oversee the progress of projects and may cease certain of the target's continued R&D. This ensures focus is directed to the most promising compounds.
Only targets that meet BBR's strict selection criteria pass on to the costly clinical research stages leading to commercialization - and initiated by the phase 1 trial on human subjects
In sum, BBR narrows down the universe of bioscience, and (yellow) in a continuous process select (and therefore also eliminate) as well as forward through R&D – “funnel through” - drug targets (grey and red) to meet the end objective of efficacious treatments available to patients (blue).
COMPETITIVE EDGE
In short, the combination of the following six key parameters makes Bridge BioResearch unique among biotechnology companies:
1. CORPORATE FOCUS
Corporate focus is devoted to metabolic disorders.
2. WORLD CLASS
World-class management and advisory team and their specialist experience in this field.
3. PATENTS
Potential value from the issued patents as well as the pending patent applications for treatment of Obesity and Type 2 Diabetes
4. AN ESTABLISHED NETWORK
Already identified cost-efficient technology acquisition targets - and access to other projects via network of companies, laboratories, institutes and universities in Europe and Asia.
5. LOW OVERHEADS
Highly flexible organization and low fixed overheads due to outsourcing to expert R&D service providers (in Denmark, Spain, UK and India).
6. EFFICIENCY
Opportunistic approach characterized by swift decision making and ability to redirect research and business efforts quickly and at low cost.
Moreover, Bridge BioResearch is confident through the examination of known molecular targets that the company will generate fundamental knowledge needed for innovation of new pharmacological treatment of obesity and accompanying metabolic disorders, including through constructing modified compounds to enhance medicinal performance.
Obesity
Obesity has reached epidemic proportions globally, with more than 1 billion adults overweight - at least 300 million of them clinically obese - and is a major contributor to the global burden of chronic disease and disability. Often coexisting in developing countries with under-nutrition, obesity is a complex condition, with serious social and psychological dimensions, affecting virtually all ages and socioeconomic groups.
Increased consumption of more energy-dense, nutrient-poor foods with high levels of sugar and saturated fats, combined with reduced physical activity, have led to obesity rates that have risen three-fold or more since 1980 in some areas of North America, the United Kingdom, Eastern Europe, the Middle East, the Pacific Islands, Australasia and China. The obesity epidemic is not restricted to industrialized societies; this increase is often faster in developing countries than in the developed world.
Obesity and overweight pose a major risk for serious diet-related chronic diseases, including type 2 diabetes, cardiovascular disease, hypertension and stroke, and certain forms of cancer. The health consequences range from increased risk of premature death, to serious chronic conditions that reduce the overall quality of life. Of especial concern is the increasing incidence of child obesity.
BBR's Focus: Metabolic Disorders
Due to BBRs focus on Obesity Type 2 Diabetes and related metabolic Disorders the company is in a unique position to succeed with its R&D. BBR aim to take patented compounds to Phase IIa and license it off to its contacts at Big Pharma within the next two to three years. This short time span (for biotech) to receive up-front and mile stone payments from Big Pharma is possible only because of BBR's unique corporate strategy
With Obesity follows higher propensity for other diseases such as Type 2 Diabetes and a number of cardiovascular diseases – the so-called metabolic syndrome.
Drug Discovery in Obesity and Type 2 Diabetes
Bridge BioResearch Limited (“BBR”) seeks to counter this challenge by discovering new drugs. Our pipeline of in-licensed intellectual property (see presentation) show great promise. Our team of scientists are on the world's cutting edge of experience in Obesity, Type 2 Diabetes and related metabolic disorders (see www.bridgebioresearch.com /people). Thus, BBR has the ability to identify and exploit the most innovative and efficacious drug targets.
BBR is different from other drug discovery companies, because we focus exclusively on drug targets for Obesity and Type 2 Diabetes, when acquiring research projects and intellectual property from universities and biotech - and then “bridge” the gap to Big Pharma's drug commercialisation.
BBR's strategy is to outsource to more time- and cost efficient CRO (Contract Research Organisations) primarily in Denmark, UK, Spain and India - instead of building up expensive and excessive in-house lab infrastructure and bureaucracy. The R&D and the patents ownership belongs to BBR until passed on to Big Pharma for further clinical development, marketing and distribution. Big Pharma then incurs all cost, but pays BBR milestone payments and royalties.
Unique Strategy: Focus with Time - and Cost Efficiency
BBR is a research project management company using global outsourcing to “bridge” the drug discovery phases towards the marketplace.
BBR's strategy is to outsource to more time- and cost efficient CRO (Contract Research Organisations) primarily in India - instead of building up expensive and excessive in-house lab infrastructure and bureaucracy. The R&D and the patents ownership belongs to BBR until passed on to Big Pharma for further clinical development, marketing and distribution. Big Pharma then incurs all cost, but pays BBR milestone payments and royalties.
BBR's strategy is to take in pre-clinical and Phase I drug targets and advance these (“bridge”) through Phase IIa, at which point (Phase IIb) the targets are sold or licensed on to big Pharma to undertake the next resource demanding tasks.
The use of funds is for research and development, which is scaleable so the burn rate is low and flexible. BBR's strategy enable faster track to market with less risk versus the traditional biotech business models
|
